Morana Jovan-Embiricos
Director/Board Member at ALLOVIR, INC.
Net worth: 9 M $ as of 2024-03-30
Profile
Morana Jovan-Embiricos is the founder and the Managing Partner of F2 Capital Ventures LLP, which was founded in 2003.
She is currently the Director of The Damon Runyon Cancer Research Foundation, AlloVir, Inc., ElevateBio LLC, Orna Therapeutics, Inc., and ReNAgade Therapeutics, Inc. Dr. Jovan-Embiricos previously served as the Independent Director of Radius Health, Inc. from 2013 to 2015, the Director of TriNetX, LLC, the Independent Director of TCR2 Therapeutics, Inc. from 2015 to 2019, the Director of Cullinan Oncology LLC, the Director of Cullinan Oncology, Inc. from 2017 to 2021, and the Venture Partner of MPM BioImpact, Inc. She also held the position of Gérant at Banque SYZ SA. Dr. Jovan-Embiricos obtained a doctorate degree from the University of Cambridge.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ALLOVIR INC
6.13% | 2023-05-10 | 6,987,027 ( 6.13% ) | 5 M $ | 2024-03-30 |
| 2023-12-30 | 207,803 ( 0.48% ) | 4 M $ | 2024-03-30 |
Morana Jovan-Embiricos active positions
| Companies | Position | Start |
|---|---|---|
| ALLOVIR, INC. | Director/Board Member | 2019-04-30 |
F2 Capital Ventures LLP
 F2 Capital Ventures LLP Investment ManagersFinance F2 Capital Ventures LLP (F2 Ventures) is an Independent Venture Capital firm founded in 2003 by Morana Jovan-Embiricos. The firm is headquartered in the UK. | Founder | 2002-12-31 |
The Damon Runyon Cancer Research Foundation
 The Damon Runyon Cancer Research Foundation Miscellaneous Commercial ServicesCommercial Services The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY. | Director/Board Member | - |
ElevateBio LLC
 ElevateBio LLC BiotechnologyHealth Technology ElevateBio LLC is a biotechnology holding company, which creates and operates a broad portfolio of cell and gene therapy companies. It builds single and multi-product companies by providing scientific founders with bench-to-bedside capabilities including scientists, manufacturing facilities, drug developers, and commercial expertise. The company was founded by David L. Hallal, Vikas Sinha, and Mitchell H. Finer and is headquartered in Cambridge, MA. | Director/Board Member | - |
Orna Therapeutics, Inc.
 Orna Therapeutics, Inc. BiotechnologyHealth Technology Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes. | Director/Board Member | - |
Renagade Therapeutics, Inc.
 Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | Director/Board Member | - |
Former positions of Morana Jovan-Embiricos
| Companies | Position | End |
|---|---|---|
| CULLINAN THERAPEUTICS, INC. | Director/Board Member | 2021-12-30 |
| TCR2 THERAPEUTICS INC. | Director/Board Member | 2019-04-30 |
| RADIUS HEALTH, INC. | Director/Board Member | 2015-02-26 |
| ░░░ ░░░░░░░░░░ ░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Training of Morana Jovan-Embiricos
| University of Cambridge | Doctorate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ALLOVIR, INC. | Health Technology |
| Private companies | 12 |
|---|---|
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Finance |
Banque SYZ SA
 Banque SYZ SA Investment ManagersFinance Banque Syz SA (Banque Syz) is the private banking subsidiary of Swiss banking group Financière Syz & Co. SA. Established in 1996, the firm is headquartered in Geneva and specializes in providing a range of asset management and advisory services including discretionary mandates and a range of Luxembourg-based mutual funds and hedge funds for private investors, high-net worth individuals, institutional clients and independent asset managers. | Finance |
The Damon Runyon Cancer Research Foundation
The Damon Runyon Cancer Research Foundation Miscellaneous Commercial ServicesCommercial Services The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY. | Commercial Services |
F2 Capital Ventures LLP
F2 Capital Ventures LLP Investment ManagersFinance F2 Capital Ventures LLP (F2 Ventures) is an Independent Venture Capital firm founded in 2003 by Morana Jovan-Embiricos. The firm is headquartered in the UK. | Finance |
TriNetX, LLC
 TriNetX, LLC Medical/Nursing ServicesHealth Services TriNetX, Inc. provides an online data network for collaborative research. It enables hospitals, academic medical centers, physician networks, practices, and pharmaceuticals to participate in collaborative research and a public and private sustainability model for research informatics. The company was founded by Bard Geesaman in 2013 and is headquartered in Cambridge, MA. | Health Services |
TCR2 Therapeutics, Inc.
 TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Cullinan Oncology LLC
 Cullinan Oncology LLC Financial ConglomeratesFinance Cullinan Oncology LLC is a biopharmaceutical company, which engages in the development of a pipeline of targeted oncology and immuno-oncology therapies for cancer diseases. The company was founded by Patrick Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA. | Finance |
ElevateBio LLC
ElevateBio LLC BiotechnologyHealth Technology ElevateBio LLC is a biotechnology holding company, which creates and operates a broad portfolio of cell and gene therapy companies. It builds single and multi-product companies by providing scientific founders with bench-to-bedside capabilities including scientists, manufacturing facilities, drug developers, and commercial expertise. The company was founded by David L. Hallal, Vikas Sinha, and Mitchell H. Finer and is headquartered in Cambridge, MA. | Health Technology |
Orna Therapeutics, Inc.
Orna Therapeutics, Inc. BiotechnologyHealth Technology Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes. | Health Technology |
| Cullinan Oncology, Inc. | |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | Health Technology |
- Stock Market
- Insiders
- Morana Jovan-Embiricos
